NOT-TR-21-013: Notice of NCATS Withdrawal from Participation in PAR-20-165, "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)"

Notice of NCATS Withdrawal from Participation in PAR-20-165, "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)"

Notice Number:

NOT-TR-21-013

Key Dates

Release Date:

Related Announcements

PAR-20-165 - Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

Effective immediately, the National Center for Advancing Translational Sciences (NCATS) withdraws its participation in PAR-20-165, "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)". Submissions intended for NCATS which are received after today’s date will be withdrawn.

Applicants interested in submitting research projects consistent with the mission of the NCATS CTSA Program are encouraged to contact a Program Officer in the Clinical and Translational Science Award Program to discuss their proposed work and identify an appropriate Funding Opportunity Announcement (FOA). For example, consideration might be given to projects through the CTSA Program Collaborative Innovation Awards opportunities.

Inquiries

Please direct all inquiries to:

Erica Rosemond, Ph.D
National Center for Advancing Translational Sciences (NCATS)

Email: [email protected]